Experimental Evidence of Harnessed Expansion of a High-Z Plasma Using the Hollow Wall Design for Indirect Drive Inertial Confinement Fusion.

The effectiveness of a dome-shaped wall covered by a thin gold foil (hollow wall) [M. Vandenboomgaerde et al., Phys. Plasmas 25, 012713 (2018)PHPAEN1070-664X10.1063/1.5008669] in holding back the high-Z plasma expansion in a gas-filled hohlraum is demonstrated for the first time in experiments reproducing the irradiation conditions of indirect drive at the ignition scale. The setup exploits a 1D geometry enabling record of the complete history of the gold expansion for 8 ns by imaging its emission in multiple x-ray energy ranges featuring either the absorption zones or the thermal emission regions. The measured expansion dynamics is well reproduced by numerical simulations. This novel wall design could now be tailored for the megajoule scale to enable the propagation of the inner beams up to the equator in low gas-filled hohlraum thus allowing the fine-tuning of the irradiation symmetry on the timescale required for ignition.

Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event.

Neutrophilic eccrine hidradenitis (NEH) is a rare neutrophilic dermatosis, first described in patients undergoing chemotherapy for a malignant haemopathy. It has polymorphous clinical features and the association of both clinical and histological features is necessary to make a diagnosis. We report the first two cases of NEH in patients treated with a BRAF inhibitor (BRAFi), either dabrafenib or vemurafenib, for a stage IV metastatic melanoma. Disseminated erythematous plaques associated with fever and polyarthralgia occurred early after the initiation of treatment and were badly tolerated. Histological analyses confirmed the diagnosis of NEH. Symptoms disappeared a few days after the cessation of treatment and introduction of topical steroids. The replacement of one BRAFi with another is a therapeutic alternative as it is not necessarily associated with a relapse of NEH. NEH can be added to the spectrum of neutrophilic dermatoses induced by BRAFis. It occurs earlier (3-4 days) than previously described drug-induced NEH (9-12 days) and may be an earlier stage of eccrine squamous syringometaplasia, which has already been reported in the context of BRAFi-treated patients.